ArticleBMC cardiovascular disorders2026
Evaluation of the ability of CTFFR to determine non-significant lesions of coronary disease based on MACE in one-year follow-up of patients (seeing beyond the stenosis: CTFFR and MACE in a one-year follow-up).
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06979427 (Evaluation of the Ability of CTFFR to Determine Non-significant Lesions of Coronary Disease Based on MACE in One-year Follow-up of Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Ability of CTFFR to Determine Non-significant Lesions of Coronary Disease Based on MACE in One-year Follow-up of Patients (Seeing Beyond the Stenosis: CTFFR and MACE in a One-Year Follow-Up)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate identification of functionally non-significant coronary lesions is crucial to optimize patient management and avoid unnecessary interventions in coronary artery disease (CAD). Computed tomography-derived fractional flow reserve (CTFFR) has emerged as a non-invasive tool for functional assessment, but its prognostic value for major adverse cardiovascular events (MACE) remains under investigation. This study aimed to evaluate the performance of CTFFR in identifying non-significant coronary lesions and its correlation with the incidence of MACE during a one-year follow-up.
methodsIn this prospective cohort study, 575 patients with suspected or known CAD and at least one intermediate coronary lesion (50–70% stenosis) underwent coronary computed tomography angiography (CCTA) with CTFFR assessment. Patients were followed for one year to monitor for MACE, defined as cardiac death, acute coronary syndrome (ACS), unplanned revascularization, or hospitalization due to cardiac causes.
resultsThe mean age of participants was 61.4 ± 11.9 years, and 54.4% were male. During one-year follow-up, 5.6% of patients experienced MACE. Patients with MACE had significantly lower NiFFR values than those without events (0.70 ± 0.10 vs. 0.78 ± 0.13; p < 0.001). Receiver operating characteristic analysis demonstrated moderate discriminatory power for predicting MACE (AUC = 0.699; 95% CI: 0.623–0.769), with sensitivity = 90.6%, specificity = 52.9%, and a notably high negative predictive value = 99.0% at a cut-off of NiFFR = 0.80.
conclusionCTFFR was linked to one-year major adverse cardiovascular events in patients with intermediate coronary lesions. While its predictive accuracy was moderate (AUC = 0.699), the high NPV supports its use as a non-invasive tool to rule out low-risk patients and guide further evaluation. .(clinicaltrials.org registration : NCT06979427/ 16.05.2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.